QLT Inc. Left by Auxilium: Favorable Risk/Reward in Uncertain Market
Research - Our view is that QLT Inc's (QLTI) board will find a way to wind down the business in a favorable manner.
Read nowSearch Results for endo health
Tax Inversion in Pharma: the New Normal or Dying Off?
Insights - Tax inversion has been a trend in the biotech and pharmaceutical industry, involvinga U.S.-based company acquiring a smaller foreign company in order to reduce paid … Continue Reading
Read now
Albany Molecular Aspires to Grow Revenue Five-Fold in As Many Years
Research - An aggressive growth plan laid out in early 2014 by management has us interested in Albany Molecular Research (AMRI). Click here to read more.
Read nowCatch Up on What We’re Trading
Recap - Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year. The stock is up nearly 190% since we first began covering the name in July of 2013. This … Continue Reading
Read now
BioDelivery Data Release Removes An Overhang
Research - BioDelivery Sciences (BDSI) and partner Endo Health Solutions (ENDP) announced on the 23rd that the second of three phase 3 trials testing one of its lead drug candidates, BEMA buprenorphine, … Continue Reading
Read now
A Glance at PropThink’s Winners and Losers in 2013
Insights - It’s New Year’s Eve. This year flew past – and so did biotech. The NASDAQ Biotechnology Index (NBI) will end the year up 60%, while … Continue Reading
Read now
“Greed is Good”: Hologic Attracts the Value Crowd
Research - This article was published for PropThink’s Premium members on Friday, November 22. Hologic (HOLX) gapped up last Thursday morning after activist investor Carl Icahn reported … Continue Reading
Read now